Streamlining Dermatology Prior Authorization: Addressing Challenges with Notable Health Workflows

For dermatology practices utilizing broader automation platforms like Notable Health for intake and RCM, optimizing prior authorization workflows for high-cost biologics and complex procedures remains a critical challenge.

While general automation platforms can streamline various aspects of clinic operations, the intricacies of dermatology prior authorization often require specialized solutions. Klivira focuses on the unique demands of PA, ensuring that even within a comprehensive automation ecosystem, critical approvals for biologics, specialty topicals, and Mohs surgery are handled with precision and efficiency, mitigating delays and denials.

The Specificity of Dermatology PA Triggers

Dermatology prior authorization is heavily concentrated around high-cost specialty drugs and specific surgical procedures. Key triggers include biologics for conditions like psoriasis (e.g., Dupixent, Cosentyx, Tremfya, Skyrizi), atopic dermatitis, and hidradenitis suppurativa, as well as Mohs micrographic surgery. These categories demand rigorous documentation and often involve complex step-therapy protocols.

Common PA-Triggering Categories in Dermatology

Biologics for psoriasis and psoriatic arthritis (TNF, IL-17, IL-23 inhibitors, JAK inhibitors)
Biologics for atopic dermatitis (dupilumab, tralokinumab, lebrikizumab, JAK inhibitors)
Biologics for hidradenitis suppurativa (adalimumab, secukinumab)
Mohs micrographic surgery for non-melanoma skin cancers
Advanced skin cancer treatments (immunotherapies, targeted therapies)
Home phototherapy prescriptions

Navigating Payer Requirements and Clinical Guidelines

Dermatology PA hinges on adherence to clinical guidelines from bodies like the AAD and NCCN. Payers require detailed documentation of diagnosis, disease severity (e.g., PASI, BSA, EASI scores), prior treatment trials (topicals, phototherapy, conventional systemics), and specific screenings (TB, hepatitis pre-biologic). For Mohs surgery, conformance to AAD Appropriate Use Criteria is paramount, often specifying tumor type and anatomical location.

Addressing Common Denial Reasons in Dermatology

Even with robust general automation, dermatology practices frequently encounter denials due to specific PA nuances. These include insufficient documentation of step-therapy compliance for biologics, lack of detailed disease severity scores, or Mohs surgery requests that don't align with payer-adopted AUC. Klivira's specialized platform is designed to preempt these issues by validating documentation against payer rules and clinical guidelines before submission.

Klivira's Approach to Dermatology Prior Authorization Automation

Klivira's platform is engineered to integrate with existing EMR systems, providing specialized automation for dermatology PA. We incorporate AAD-guideline-aware step-therapy logic, AUC validation for Mohs surgery, and intelligent routing for medical-vs-pharmacy benefit distinctions. This ensures that whether a practice uses Notable Health for broader RCM or not, their prior authorization process for dermatology-specific treatments is optimized, reducing manual effort and improving approval rates for chronic biologic treatments and high-volume procedures.

Optimizing EMR and Payer Touchpoints for Derm PA

Effective dermatology prior authorization requires seamless interaction between the EMR and various payer channels. Klivira's platform streamlines this by capturing necessary clinical data from the EMR, populating X12 278 transactions or ePA portals, and managing periodic re-authorization cycles for chronic conditions. This reduces the burden on PA coordinators, allowing them to focus on complex cases rather than manual data entry across multiple systems and payer interfaces.

Frequently asked questions

How does Klivira handle step therapy requirements for dermatology biologics?

Klivira's platform incorporates AAD-guideline-aware logic to guide users through required step-therapy protocols for biologics like those for psoriasis and atopic dermatitis. It prompts for documentation of prior topical or conventional systemic therapy trials, helping ensure submissions meet payer criteria and reduce denials.

Can Klivira automate prior authorization for Mohs micrographic surgery?

Yes, Klivira automates Mohs surgery PA by validating requests against payer policies and AAD Appropriate Use Criteria. The system helps ensure that documentation regarding tumor type, site (especially cosmetically/functionally sensitive areas), and prior treatments is complete and compliant before submission.

How does Klivira manage recurring prior authorizations for chronic dermatology conditions?

For chronic conditions requiring long-term biologic treatment, Klivira's platform tracks authorization expiration dates and automates the re-authorization workflow. This proactive management ensures continuous coverage, preventing treatment interruptions and reducing administrative burden for dermatology practices.

Does Klivira integrate with my existing EMR to pull dermatology-specific patient data?

Klivira is designed for deep integration with various EMR systems, leveraging standards like SMART on FHIR where available. This allows for automated extraction of critical dermatology-specific data, such as PASI, BSA, or EASI scores, and prior treatment history, directly into the PA workflow, minimizing manual data entry.

How does Klivira differentiate between medical and pharmacy benefit for dermatology medications?

Klivira's platform includes intelligent routing capabilities that distinguish between medical and pharmacy benefit for dermatology medications, such as self-injectable biologics versus clinic-administered infusions. This ensures that prior authorization requests are submitted through the correct channel (medical claim or NCPDP SCRIPT for ePA), streamlining the process and avoiding misrouted denials.